Business

New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.

Bristol-Myers Squibb to Buy Celgene for $74bn

Bristol-Myers Squibb (BMS) has announced intentions to buy Celgene for $74bn. This transaction, the fourth largest such deal in pharma history, will give BMS access to several cancer franchises, including experimental cell therapies which attack tumours.

Most Orphan Drugs Performing Poorly, Report Finds

The latest annual report from Trinity Partners has found that orphan disease drugs often perform poorly at launch and continue to underachieve after three years of sales. At the other end of the spectrum, the most successful drugs on the market were for non-orphan diseases such as cancer and HIV.

Illumina Buys PacBio for $1.2bn

DNA sequencing company Pacific Biosciences (PacBio) is being bought for $1.2bn by bigger rival Illumina, it was announced yesterday. The deal represents a 71% premium on yesterday’s closing price for PacBio, and is the largest that Illumina has ever made.

GSK and 23andMe Agree to $300M Deal

Pharmaceutical giant GlaxoSmithKline has bought a $300 million stake in genetic DTC testing company 23andMe to help further their genetics-based drug discovery.